SynthesisJAMA2023
Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.
Synthesis in JAMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Current guidelines on screening, diagnosis and management of dyslipidaemia in childhood: a systematic review.Pediatric research · 2026Pooled it
- Examining Food Security, Fruit and Vegetable Intake, and Cardiovascular Disease Risk Outcomes of Produce Prescription (PPR) Programs: A Systematic Review.Journal of nutrition education and behavior · 2024Pooled it
- Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review.PharmacoEconomics · 2024Pooled it
- Dyslipidemia in Lebanese children and adolescents: parents' knowledge and practices.BMC public health · 2026Article
- Test the Child, Uncover the High-Risk Parent: A Call to Expand Universal Pediatric Lipid Screening.American journal of lifestyle medicine · 2026Article
- Lipid Screening for Cardiovascular Risk in Youth: A Narrative Review of Current Guidelines and Potential Use of Nonfasting Measures.CJC pediatric and congenital heart disease · 2026Review
- The prevention of adult cardiovascular disease must begin in childhood: evidence and imperative.Nature reviews. Cardiology · 2026Review
- Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.Journal of clinical medicine research · 2026Review
- Article
- Impact of anti-peptic ulcer disease (PUD) medications on hyperlipidemia risk in patients with PUD: a population-based retrospective cohort study.Therapeutic advances in endocrinology and metabolism · 2026Article
- Knowledge, attitudes, and practices of Lebanese physicians on the screening of pediatric dyslipidemias: a KAP cross-sectional study.Frontiers in endocrinology · 2026Article
- Opportunities and Challenges in Translating Genomics into Population Health Impact: Lessons from Familial Hypercholesterolemia.Public health genomics · 2026Review
- Dyslipidemia Assessed in Pediatric Patients: Validation of LDL-C Assessed by Friedewald Formula, Direct Assessment, and Sampson-NIH Formula.Diagnostics (Basel, Switzerland) · 2025Article
- Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk Reduction.Journal of the American Heart Association · 2025Review
- Demystifying the nuances of the lipid patient: a guide for primary care providers.American journal of preventive cardiology · 2025Review
- State-of-the-art review: The value of leveraging evidence and data (LEAD) in pediatric screening for familial hypercholesterolemia.American journal of preventive cardiology · 2025Review
- Trajectory of Cardiovascular Health Across Childhood and Adolescence.JAMA cardiology · 2025Article
- Cholesterol screening by nativity status in pediatric patients receiving care in United States community-based clinics.Preventive medicine · 2025Article
- Body composition shapes cardiometabolic risk in children with multifactorial dyslipidemia.Frontiers in nutrition · 2025Article
- Tracking of serum lipids from prepuberty to young adulthood: results from the KiGGS cohort study.Lipids in health and disease · 2024Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- SummaryForPatientsIn
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Familial hypercholesterolemia and multifactorial dyslipidemia are 2 conditions that cause abnormally high lipid levels in children, which can lead to premature cardiovascular events (eg, myocardial infarction and stroke) and death in adulthood. Objective: The US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for lipid disorders in asymptomatic children and adolescents. Population: Asymptomatic children and adolescents 20 years or younger without a known diagnosis of a lipid disorder. Evidence Assessment: The USPSTF concludes that the current evidence is insufficient and the balance of benefits and harms for screening for lipid disorders in asymptomatic children and adolescents 20 years or younger cannot be determined. Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents 20 years or younger. (I statement).
Indexed as
Identifiers
37462699What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.